Advances in precision treatment promise to greatly improve the extent to which therapies for mental disorders are better matched to patient characteristics.At the same,we need to ensure that more readily disseminable ...Advances in precision treatment promise to greatly improve the extent to which therapies for mental disorders are better matched to patient characteristics.At the same,we need to ensure that more readily disseminable and available nonprecison treatments are further developed as well.These treatments refer to standardized interven-tions that do not have to be individualized and are more readily available.Impetus for this call stems from the treatment gap,namely,the huge difference in the proportion of individuals who are in need of mental health services and who actually receive any form of treatment.The prevalence rates for mental disorders worldwide are high and in low-,middle-,and high-income countries and the vast majority of individuals in need of services receive none.To address the need,we need interventions that can reach large numbers of individuals and espe-cially target those individuals least likely to receive services.Standardized treatments that can be widely applied may be in a better position at present to reach people in need who otherwise receive no care.展开更多
The ZnO-Al films were prepared by R.F. magnetron sputtering system using a Zn-Al target (with purity of (99.99%).) The obtained films were characterized by X-ray diffraction, SEM and optical and electrical measurement...The ZnO-Al films were prepared by R.F. magnetron sputtering system using a Zn-Al target (with purity of (99.99%).) The obtained films were characterized by X-ray diffraction, SEM and optical and electrical measurements. The experimental results show that the properties of ZnO films can be further improved by annealing treatment. The crystallinity of ZnO films becomes better, and the optical gap energy is decreased, but thermoelectric power is enhanced after heat treatment. The optical gap energy decreases from 3.75 eV to 3.68 eV when the annealing temperature increases from 25 ℃ to 400 ℃.This can be ascribed to the decrease of carrier concentration, resulting in Burstein shift.展开更多
AIM: To compare adherence, response, and remission with light treatment in African-American and Caucasian patients with Seasonal Affective Disorder.METHODS: Seventy-eight study participants, agerange 18-64(51 African-...AIM: To compare adherence, response, and remission with light treatment in African-American and Caucasian patients with Seasonal Affective Disorder.METHODS: Seventy-eight study participants, agerange 18-64(51 African-Americans and 27 Caucasians)recruited from the Greater Baltimore Metropolitan area, with diagnoses of recurrent mood disorder with seasonal pattern, and confirmed by a Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders-Ⅳ, were enrolled in an open label study of daily bright light treatment. The trial lasted6 wk with flexible dosing of light starting with 10000 lux bright light for 60 min daily in the morning. At the end of six weeks there were 65 completers. Three patients had Bipolar Ⅱ disorder and the remainder had Major depressive disorder. Outcome measures were remission(score ≤ 8) and response(50% reduction)in symptoms on the Structured Interview Guide for the Hamilton Rating Scale for Depression(SIGH-SAD)as well as symptomatic improvement on SIGH-SAD and Beck Depression Inventory-Ⅱ. Adherence was measured using participant daily log. Participant groups were compared using t-tests, chi square, linear and logistic regressions. RESULTS: The study did not find any significant group difference between African-Americans and their Caucasian counterparts in adherence with light treatment as well as in symptomatic improvement.While symptomatic improvement and rate of treatment response were not different between the two groups,African-Americans, after adjustment for age, gender and adherence, achieved a significantly lower remission rate(African-Americans 46.3%; Caucasians 75%; P =0.02).CONCLUSION: This is the first study of light treatment in African-Americans, continuing our previous work reporting a similar frequency but a lower awareness of SAD and its treatment in African-Americans. Similar rates of adherence, symptomatic improvement and treatment response suggest that light treatment is a feasible, acceptable, and beneficial treatment for SAD in African-American patients. These results should lead to intensifying education initiatives to increase awareness of SAD and its treatment in African-American communities to increased SAD treatment engagement.In African-American vs Caucasian SAD patients a remission gap was identified, as reported before with antidepressant medications for non-seasonal depression, demanding sustained efforts to investigate and then address its causes.展开更多
文摘Advances in precision treatment promise to greatly improve the extent to which therapies for mental disorders are better matched to patient characteristics.At the same,we need to ensure that more readily disseminable and available nonprecison treatments are further developed as well.These treatments refer to standardized interven-tions that do not have to be individualized and are more readily available.Impetus for this call stems from the treatment gap,namely,the huge difference in the proportion of individuals who are in need of mental health services and who actually receive any form of treatment.The prevalence rates for mental disorders worldwide are high and in low-,middle-,and high-income countries and the vast majority of individuals in need of services receive none.To address the need,we need interventions that can reach large numbers of individuals and espe-cially target those individuals least likely to receive services.Standardized treatments that can be widely applied may be in a better position at present to reach people in need who otherwise receive no care.
文摘The ZnO-Al films were prepared by R.F. magnetron sputtering system using a Zn-Al target (with purity of (99.99%).) The obtained films were characterized by X-ray diffraction, SEM and optical and electrical measurements. The experimental results show that the properties of ZnO films can be further improved by annealing treatment. The crystallinity of ZnO films becomes better, and the optical gap energy is decreased, but thermoelectric power is enhanced after heat treatment. The optical gap energy decreases from 3.75 eV to 3.68 eV when the annealing temperature increases from 25 ℃ to 400 ℃.This can be ascribed to the decrease of carrier concentration, resulting in Burstein shift.
基金Supported by The National Institute of Mental Health of the National Institutes of Health under award No.1R34MH073797-01A2(PI Postolache TT)in part by the National Institutes of Health award No.K12RR023250-01(PI Reeves GM)by the National Center for Research Resources of the National Institutes of Health award No.M01 RR 16500(General Clinical Research Program)
文摘AIM: To compare adherence, response, and remission with light treatment in African-American and Caucasian patients with Seasonal Affective Disorder.METHODS: Seventy-eight study participants, agerange 18-64(51 African-Americans and 27 Caucasians)recruited from the Greater Baltimore Metropolitan area, with diagnoses of recurrent mood disorder with seasonal pattern, and confirmed by a Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders-Ⅳ, were enrolled in an open label study of daily bright light treatment. The trial lasted6 wk with flexible dosing of light starting with 10000 lux bright light for 60 min daily in the morning. At the end of six weeks there were 65 completers. Three patients had Bipolar Ⅱ disorder and the remainder had Major depressive disorder. Outcome measures were remission(score ≤ 8) and response(50% reduction)in symptoms on the Structured Interview Guide for the Hamilton Rating Scale for Depression(SIGH-SAD)as well as symptomatic improvement on SIGH-SAD and Beck Depression Inventory-Ⅱ. Adherence was measured using participant daily log. Participant groups were compared using t-tests, chi square, linear and logistic regressions. RESULTS: The study did not find any significant group difference between African-Americans and their Caucasian counterparts in adherence with light treatment as well as in symptomatic improvement.While symptomatic improvement and rate of treatment response were not different between the two groups,African-Americans, after adjustment for age, gender and adherence, achieved a significantly lower remission rate(African-Americans 46.3%; Caucasians 75%; P =0.02).CONCLUSION: This is the first study of light treatment in African-Americans, continuing our previous work reporting a similar frequency but a lower awareness of SAD and its treatment in African-Americans. Similar rates of adherence, symptomatic improvement and treatment response suggest that light treatment is a feasible, acceptable, and beneficial treatment for SAD in African-American patients. These results should lead to intensifying education initiatives to increase awareness of SAD and its treatment in African-American communities to increased SAD treatment engagement.In African-American vs Caucasian SAD patients a remission gap was identified, as reported before with antidepressant medications for non-seasonal depression, demanding sustained efforts to investigate and then address its causes.
